Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Eloxx Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Eloxx Pharmaceuticals, Inc.’s stock price such as:

• Eloxx Pharmaceuticals, Inc.’s current stock price and volume
• Why Eloxx Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ELOX from analysts
• ELOX’s stock price momentum as measured by its relative strength

About Eloxx Pharmaceuticals, Inc. (ELOX)

Before we jump into Eloxx Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Want to learn more about Eloxx Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eloxx Pharmaceuticals, Inc..

Eloxx Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Eloxx Pharmaceuticals, Inc.’s stock price was $17.430.

Eloxx Pharmaceuticals, Inc. is up 31.05% from its previous closing price of $13.300.

During the last market session, Eloxx Pharmaceuticals, Inc.’s stock traded between $13.790 and $18.420. Currently, there are approximately 4.38 million shares outstanding for Eloxx Pharmaceuticals, Inc..

Eloxx Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Eloxx Pharmaceuticals, Inc. Stock Price History

Eloxx Pharmaceuticals, Inc.’s (ELOX) price is currently up 25.58% so far this month.

During the month of July, Eloxx Pharmaceuticals, Inc.’s stock price has reached a high of $18.420 and a low of $10.510.

Over the last year, Eloxx Pharmaceuticals, Inc. has hit prices as high as $18.421 and as low as $0.000. Year to date, Eloxx Pharmaceuticals, Inc.’s stock is up 1584445.45%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eloxx Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Eloxx Pharmaceuticals, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Eloxx Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Eloxx Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eloxx Pharmaceuticals, Inc. (ELOX) by visiting AAII Stock Evaluator.

Relative Price Strength of Eloxx Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Eloxx Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 32938.00%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Eloxx Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eloxx Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Eloxx Pharmaceuticals, Inc.’s stock price is $17.430, which is up 31.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Eloxx Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.